Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 10 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; calcium hydrogen phosphate dihydrate; iron oxide red; maize starch; mannitol - hypertension: lisodrate tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril (as dihydrate) in severe hypertension or renovascular hypertension. congestive heart failure: lisodrate tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that lisodrate tablets be administered with a diuretic. acute myocardial infarction: lisodrate tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. lisodrate tablets may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 5 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; mannitol; magnesium stearate; maize starch; iron oxide red - hypertension: lisodrate tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril (as dihydrate) in severe hypertension or renovascular hypertension. congestive heart failure: lisodrate tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that lisodrate tablets be administered with a diuretic. acute myocardial infarction: lisodrate tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. lisodrate tablets may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 2.5 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; magnesium stearate; mannitol; maize starch - hypertension: lisodrate tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril (as dihydrate) in severe hypertension or renovascular hypertension. congestive heart failure: lisodrate tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that lisodrate tablets be administered with a diuretic. acute myocardial infarction: lisodrate tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. lisodrate tablets may be initiated within 24 hours of an acute myocardial infarction.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - lisinopril dihydrate 10.89mg equivalent to 10 mg lisinopril;   - tablet - 10 mg - active: lisinopril dihydrate 10.89mg equivalent to 10 mg lisinopril   excipient: calcium hydrogen phosphate dihydrate colloidal silicon dioxide magnesium stearate mannitol pregelatinised maize starch starch - lisinopril is indicated in the treatment of essential hypertension and in renovascular hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - lisinopril dihydrate 21.78mg equivalent to 20 mg lisinopril;   - tablet - 20 mg - active: lisinopril dihydrate 21.78mg equivalent to 20 mg lisinopril   excipient: calcium hydrogen phosphate dihydrate colloidal silicon dioxide pregelatinised maize starch magnesium stearate mannitol starch - lisinopril is indicated in the treatment of essential hypertension and in renovascular hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - lisinopril dihydrate 5.445mg equivalent to 5.0 mg lisinopril;   - tablet - 5 mg - active: lisinopril dihydrate 5.445mg equivalent to 5.0 mg lisinopril   excipient: calcium hydrogen phosphate dihydrate colloidal silicon dioxide pregelatinised maize starch magnesium stearate mannitol starch - lisinopril is indicated in the treatment of essential hypertension and in renovascular hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents.

United States - English - NLM (National Library of Medicine)

cardinal health - lisinopril (unii: e7199s1ywr) (lisinopril anhydrous - unii:7q3p4bs2fd) - lisinopril 5 mg - lisinopril tablets are indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety

United States - English - NLM (National Library of Medicine)

mylan institutional inc. - lisinopril (unii: e7199s1ywr) (lisinopril anhydrous - unii:7q3p4bs2fd) - lisinopril 5 mg - lisinopril tablets are indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety

United States - English - NLM (National Library of Medicine)

golden state medical supply inc. - lisinopril (unii: e7199s1ywr) (lisinopril anhydrous - unii:7q3p4bs2fd) - lisinopril 2.5 mg - lisinopril tablets are indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety

United States - English - NLM (National Library of Medicine)

safecor health, llc - lisinopril (unii: e7199s1ywr) (lisinopril anhydrous - unii:7q3p4bs2fd) - lisinopril 10 mg - lisinopril tablets usp are indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a vari